EFFICACY AND SAFETY OF TIRZEPATIDE  FOR OBESITY MANAGEMENT IN NON-DIABETIC INDIVIDUALS:  A SYSTEMATIC REVIEW AND META-ANALYSIS

Hà Văn Tân; Vũ Thị Tường Vân; Lê Hồng Khanh; Bùi Thị Xuân Mai; Lã Trọng Quyền; Trần Thu Phương

doi:10.34238/tnu-jst.12801

EFFICACY AND SAFETY OF TIRZEPATIDE FOR OBESITY MANAGEMENT IN NON-DIABETIC INDIVIDUALS: A SYSTEMATIC REVIEW AND META-ANALYSIS

About this article

Received: 14/05/25 Revised: 30/09/25 Published: 30/09/25

Authors

1. Ha Van Tan , Spa Vitória
2. Vu Thi Tuong Van, Bac Giang Rehabilitation Hospital
3. Le Hong Khanh, Novopharm Company Limited
4. Bui Thi Xuan Mai, Mbclinic
5. La Trong Quyen, Hai Ba Trung Health Centre
6. Tran Thu Phuong, Thanh Tri Health Centre

Abstract

Tirzepatide has emerged as a promising therapy for obesity management. This systematic review and meta-analysis evaluated its efficacy and safety in non-diabetic individuals with obesity. A comprehensive search of PubMed, Google Scholar, Cochrane, and ClinicalTrials.gov databases identified five randomized controlled trials meeting inclusion criteria. Data extraction and quality assessment were independently performed by six reviewers.The primary outcome was the mean difference (MD) in body weight, with a 95% confidence interval (CI). Statistical analyses were conducted using R software (version 4.4.2) with the meta and metafor packages. Pooled analysis showed a significantly greater weight reduction in the tirzepatide group compared to placebo (MD: -17.55 kg; 95% CI: -32.15 to -2.95; p = 0.02; I² = 100%). High heterogeneity (I² = 100%) suggests variability across studies, indicating the need for subgroup and sensitivity analyses.Despite this heterogeneity, findings support tirzepatide as an effective weight-loss option for non-diabetic individuals with obesity. Further research is necessary to evaluate long-term safety and identify subgroups that may benefit most.

Keywords

Tirzepatide; Obesity; Overweight; Systematic review; Meta-analysis

Full Text:

PDF (Tiếng Việt)

References

[1] G. A. Bray, The Battle of the Bulge: A History of Obesity Research. Dorrance Publishing Company, 2007.

[2] M. D. Jensen et al., “2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society,” Circulation, vol. 129, no. 25, Suppl. 2, pp. S102–S138, Jun. 2014, doi: 10.1161/01.cir.0000437739.71477.ee.

[3] World Health Organization, “WHO Discussion Paper: Draft recommendations for the prevention and management of obesity over the life course, including potential targets,” 2021. [Online]. Available: https://www.who.int/publications/m/item/who-discussion-paper-draft-recommendations-for-the-prevention-and-management-of-obesity-over-the-life-course-including-potential-targets. [Accessed Apr. 03, 2025].

[4] P. G. Kopelman, “Obesity as a medical problem,” Nature, vol. 404, no. 6778, pp. 635–643, Apr. 2000, doi: 10.1038/35007508.

[5] S. A. Grover et al., “Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study,” Lancet Diabetes Endocrinol, vol. 3, no. 2, pp. 114–122, Feb. 2015, doi: 10.1016/S2213-8587(14)70229-3.

[6] S. J. Olshansky et al., “A potential decline in life expectancy in the United States in the 21st century,” N. Engl. J. Med., vol. 352, no. 11, pp. 1138–1145, Mar. 2005, doi: 10.1056/NEJMsr043743.

[7] A. Peeters et al., “Obesity in adulthood and its consequences for life expectancy: A life-table analysis,” Ann. Intern. Med., vol. 138, no. 1, pp. 24–32, Jan. 2003, doi: 10.7326/0003-4819-138-1-200301070-00008.

[8] Examination Committee of Criteria for “Obesity Disease” in Japan and Japan Society for the Study of Obesity, “New criteria for ‘obesity disease’ in Japan,” Circ. J., vol. 66, no. 11, pp. 987–992, Nov. 2002, doi: 10.1253/circj.66.987.

[9] B.-Y. Kim et al., “2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea,” J. Obes. Metab. Syndr., vol. 30, no. 2, pp. 81–92, Jun. 2021, doi: 10.7570/jomes21022.

[10] World Health Organization, “Obesity and overweight,” 2025. [Online]. Available: https://www.who.int/ news-room/fact-sheets/detail/obesity-and-overweight. [Accessed Apr. 03, 2025].

[11] W. T. Garvey, J. I. Mechanick, E. M. Brett, A. J. Garber, D. L. Hurley, A. M. Jastreboff, K. Nadolsky, R. Pessah-Pollack, and R. Plodkowski, “Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines, “American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity,” Endocr Pract., vol. 22, suppl. 3, pp. 1–203, 2016. [Online]. Available: https://www.endocrinepractice.org/article/S1530-891X(20)44630-0/fulltext. [Accessed Apr. 03, 2025].

[12] AGA Clinical Guidelines Committee, E. Grunvald, R. Shah, R. Hernaez, A. K. Chandar, O. Pickett-Blakely, L. M. Teigen, T. Harindhanavudhi, S. Sultan, S. Singh, and P. Davitkov, “AGA clinical practice guideline on pharmacological interventions for adults with obesity,” Gastroenterology, vol. 163, no. 5, pp. 1198–1225, 2022. [Online]. Available: https://www.gastrojournal.org/article/S0016-5085(22)01026-5/fulltext. [Accessed Apr. 03, 2025].

[13] A. M. Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” N. Engl. J. Med., vol. 387, no. 3, pp. 205–216, Jul. 2022, doi: 10.1056/NEJMoa2206038.

[14] M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” BMJ, vol. 372, Mar. 2021, Art. no. n71, doi: 10.1136/bmj.n71.

[15] Cochrane Collaboration, “Chapter 2: Determining the scope of the review and the questions it will address,” 2024. [Online]. Available: https://training.cochrane.org/handbook/current/chapter-02. [Accessed Apr. 03, 2025].

[16] J. P. T. Higgins et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” BMJ, vol. 343, Oct. 2011, Art. no. d5928, doi: 10.1136/bmj.d5928.

[17] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, Sep. 2003, doi: 10.1136/bmj.327.7414.557.

[18] T. A. Wadden et al., “Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial,” Nat. Med., vol. 29, no. 11, pp. 2909–2918, Nov. 2023, doi: 10.1038/s41591-023-02597-w.

[19] L. J. Aronne et al., “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial,” JAMA, vol. 331, no. 1, pp. 38–48, Jan. 2024, doi: 10.1001/jama.2023.24945.

[20] NCT04844918, “A study of tirzepatide (LY3298176) in participants with obesity disease,” ClinicalTrials.gov, 2021. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT04844918. [Accessed Apr. 03, 2025].

[21] L. Zhao et al., “Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial,” JAMA, vol. 332, no. 7, pp. 551–560, Aug. 2024, doi: 10.1001/jama.2024.9217.

[22] S. C. Morton, J. L. Adams, M. J. Suttorp, and P. G. Shekelle, “Introduction,” in Meta-regression Approaches: What, Why, When, and How?, Agency for Healthcare Research and Quality (US), 2004. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK43897/. [Accessed Apr. 03, 2025].

DOI: https://doi.org/10.34238/tnu-jst.12801

Refbacks

There are currently no refbacks.



Remember me